Golden State Equity Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.8M Buy
8,490
+8,487
+282,900% +$10M 0.58% 27
2026
Q2
$3.6K Sell
3
-7,429
-100% -$7.59M 0.01% 267
2026
Q1
$6.84M Buy
7,432
+3,897
+110% +$3.95M 0.52% 32
2025
Q4
$3.8M Buy
3,535
+440
+14% +$421K 0.61% 28
2025
Q3
$2.36M Sell
3,095
-9
-0.3% -$6.7K 0.4% 48
2025
Q2
$2.42M Buy
3,104
+582
+23% +$452K 0.45% 46
2025
Q1
$2.08M Buy
2,522
+38
+2% +$31.6K 0.41% 56
2024
Q4
$1.92M Buy
2,484
+110
+5% +$91.1K 0.37% 58
2024
Q3
$2.1M Buy
2,374
+38
+2% +$34.2K 0.33% 65
2024
Q2
$2.11M Buy
+2,336
New +$1.87M 0.44% 46
2023
Q4
$1.45M Buy
2,481
+271
+12% +$158K 0.35% 71
2023
Q3
$1.19M Sell
2,210
-96
-4% -$49.5K 0.33% 79
2023
Q2
$1.08M Buy
2,306
+18
+0.8% +$7.55K 0.3% 81
2023
Q1
$786K Buy
+2,288
New +$772K 0.43% 71
2022
Q1
$379K Hold
1,322
– – 0.19% 130
2021
Q4
$365K Sell
1,322
-8
-0.6% -$2.03K 0.18% 109
2021
Q3
$307K Sell
1,330
-68
-5% -$16.8K 0.13% 161
2021
Q2
$321K Sell
1,398
-446
-24% -$89.6K 0.12% 169
2021
Q1
$344K Buy
1,844
+486
+36% +$95.1K 0.2% 113
2020
Q4
$229K Buy
+1,358
New +$203K 0.16% 149

Other funds holding LLY

Golden State Equity Partners's LLY Position: Q3 2026 in Review

Golden State Equity Partners increased its Eli Lilly (LLY) stake by 282,900% in Q3 2026, buying an estimated $10M and bringing the position to 8,490 shares worth $9.8M. The position accounts for 0.58% of the portfolio, ranked #27.

Golden State Equity Partners first reported a position in LLY in Q4 2020 and has held it in 20 quarters since. 4,608 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Golden State Equity Partners held 8,490 shares of Eli Lilly worth $9.8M as of Q3 2026.
  • Golden State Equity Partners bought 8,487 Eli Lilly shares in Q3 2026, an estimated $10M.
  • Eli Lilly made up 0.58% of Golden State Equity Partners's portfolio in Q3 2026, its #27 holding.
  • Golden State Equity Partners first reported a position in Eli Lilly in Q4 2020 and has held it in 20 quarters since.
  • 4,608 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Golden State Equity Partners's 13F filing for Q3 2026, filed 3 Nov 2026.